Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy

Advanced Drug Delivery Reviews

Volumn 63, Issue 14-15, 2011, Pages 1340-1351

  Prakash, Satya ^a   Malhotra, Meenakshi ^a   Shao, Wei ^a   Tomaro Duchesneau, Catherine ^a   Abbasi, Sana ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer therapy; Carbon nanotubes; Drug delivery; Microcapsule; Nanohybrids; Polymeric nanoparticles

Indexed keywords

CANCER THERAPEUTICS; CANCER THERAPY; CURRENT STATUS; DISEASE DIAGNOSIS; DISEASE PREVENTION; DRUG DELIVERY CARRIER; DRUG DELIVERY SYSTEM; FUNCTIONALIZED CARBON NANOTUBES; MICROCAPSULES; NANO-HYBRID MATERIALS; NANOHYBRIDS; POLYMERIC NANOPARTICLES; PRODUCTION PARAMETERS; TARGETED DELIVERY; TARGETING MOLECULES; THERAPEUTIC EFFICACY;

CARBON; CARBON NANOTUBES; CHEMOTHERAPY; DIAGNOSIS; DISEASES; DRUG DELIVERY; NANOPARTICLES; NANOSTRUCTURED MATERIALS; ONCOLOGY; RADIOTHERAPY;

FUNCTIONAL POLYMERS;

10 HYDROXYCAMPTOTHECIN; CARBON NANOTUBE; CISPLATIN; CYSTATIN; DEXTRAN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; MACROGOL; METHOTREXATE; MULTI WALLED NANOTUBE; NANOMATERIAL; NANOPARTICLE; PACLITAXEL; POLOXAMER; POLY(ETHYL 2 CYANOACRYLATE); POLY(ISOBUTYL 2 CYANOACRYLATE); POLYACRYLAMIDE; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER; POLYSORBATE 80; POLYVINYL ALCOHOL; POVIDONE; QUANTUM DOT; SINGLE WALLED NANOTUBE; TAMOXIFEN; UNINDEXED DRUG; ZINOSTATIN;

BIOCOMPATIBILITY; BREAST CANCER; CANCER THERAPY; COLON CANCER; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IC 50; INFRARED RADIATION; LIVER CELL CARCINOMA; MICELLE; MICROENCAPSULATION; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SOLID TUMOR; SUSTAINED DRUG RELEASE; SYNTHESIS; TUMOR CELL DESTRUCTION;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; MOLECULAR STRUCTURE; NANOTECHNOLOGY; NANOTUBES, CARBON; NEOPLASMS; POLYMERS; SOLUBILITY;

EID: 81355138643     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.06.013     Document Type: Review

References (179)

1. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
3. Stewart B.W., Kleihues P. World Cancer Report 2003, World Health Organization.
4. World Health Organization. Cancer. Fact Sheet #297 2009.
5. Aggarwal S. Targeted cancer therapies. Nat. Rev. Drug Discov. 2010, 9:427-428.
6. Shih H.A., Loeffler J.S., Tarbell N.J. Late Effects of CNS Radiation Therapy 2009, 23-41.
7. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8:193-204.
8. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7:573-584.
9. Chaney S.G., Campbell S.L., Temple B., Bassett E., Wu Y., Faldu M. Protein interactions with platinum-DNA adducts: from structure to function. J. Inorg. Biochem. 2004, 98:1551-1559.
10. Chen M.J., Shimada T., Moulton A.D., Cline A., Humphries R.K., Maizel J., Nienhuis A.W. The functional human dihydrofolate reductase gene. J. Biol. Chem. 1984, 259:3933-3943.
11. Morales C., Garcia M.J., Ribas M., Miro R., Munoz M., Caldas C., Peinado M.A. Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol. Cancer Ther. 2009, 8:424-432.
12. Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005, 53:3-11.
13. Graham J., Muhsin M., Kirkpatrick P. Oxaliplatin. Nat. Rev. Drug Discov. 2004, 3:11-12.
14. Meriwether W.D., Bachur N.R. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res. 1972, 32:1137-1142.
15. Frederick C.A., Williams L.D., Ughetto G., Van der Marel G.A., Van Boom J.H., Rich A., Wang A.H.J. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29:2538-2549.
16. Mukherjee A., Lavery R., Bagchi B., Hynes J.T. Simulation Study of the Molecular Mechanism of Intercalation of the Anti-Cancer Drug Daunomycin into DNA 2009, 165-180.
17. van Maanen J.M.S., Retel J., de Vries J., Pinedo H.M. Mechanism of action of antitumor drug etoposide: a review. J. Natl Cancer Inst. 1988, 80:1526-1533.
18. Sinha B.K., Haim N., Dusre L., Kerrigan D., Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 1988, 48:5096-5100.
19. Wurzer J.C., Tallarida R.J., Sirover M.A. New mechanism of action of the cancer chemotherapeutic agent 5-fluorouracil in human cells. J. Pharmacol. Exp. Ther. 1994, 269:39-43.
20. Eaglstein W.H., Weinstein G.D., Frost P. Fluorouracil: mechanism of action in human skin and actinic keratoses: I. Effect on DNA synthesis in vivo. Arch. Dermatol. 1970, 101:132-139.
21. Parker W.B., Cheng Y.C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol. Ther. 1990, 48:381-395.
22. Yarbro J.W. Further studies on the mechanism of action of hydroxyurea. Cancer Res. 1968, 28:1082-1087.
23. Krakoff I.H., Brown N.C., Reichard P. Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res. 1968, 28:1559-1565.
24. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 1992, 19:1-10.
25. Salser J.S., Balis M.E. The mechanism of action of 6-mercaptopurine. Cancer Res. 1965, 25:539-543.
26. Panetta J.C., Evans W.E., Cheok M.H. Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells. Br. J. Cancer 2005, 94:93-100.
27. Schiff B.P., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
28. Morse D.L., Gray H., Payne C.M., Gillies R.J. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol. Cancer Ther. 2005, 4:1495-1504.
29. Herbst R.S., Khuri F.R. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat. Rev. 2003, 29:407-415.
30. Sawka C.A., Pritchard K.I., Paterson A.H.G., Sutherland D.J.A., Thomson D.B., Shelley W.E., Myers R.E., Mobbs B.G., Malkin A., Meakin J.W. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma. Cancer Res. 1986, 46:3152-3156.
31. Wood A.J.J., Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J. Med. 2009, 339:1609-1618.
32. Gigant B., Wang C., Ravelli R.B.G., Roussi F., Steinmetz M.O., Curmi P.A., Sobel A., Knossow M. Structural basis for the regulation of tubulin by vinblastine. Nature 2005, 435:519-522.
33. Himes R.H. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol. Ther. 1991, 51:257-267.
34. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985, 260:14873-14878.
35. Liu F.Leroy, Desai S.H., Li T.-K., Mao Y., Sun M., Sim S.-P. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 2006, 922:1-10. (The Camptothecins: Unfolding their Anticancer Potential).
36. Le Tourneau C., Faivre S., Raymond E. New developments in multitargeted therapy for patients with solid tumours. Cancer Treat. Rev. 2008, 34:37-48.
37. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30:592-599.
38. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5:1909-1917.
39. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2005, 94:15-21.
40. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34:592-602.
41. Hoffman A.S. The origins and evolution of "controlled" drug delivery systems. J. Control. Release 2008, 132:153-163.
42. Abraxane. Abraxis BioScience, LLC http://www.abraxane.com.
43. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
44. Pastorin G., Wu W., Wieckowski S., Briand J.P., Kostarelos K., Prato M., Bianco A. Double functionalisation of carbon nanotubes for multimodal drug delivery. Chem. Commun. 2006, 11:1182-1184.
45. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents drug-polymer conjugates. Clin. Cancer Res. 1999, 5:83-94.
46. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., Boer R.F., Pluim D., Beijnen J.H., Schellens J.H.M., Droz J.P. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3weeks in patients with solid tumors. Clin. Cancer Res. 2004, 10:3386-3395.
47. Nowotnik D.P., Cvitkovic E. ProLindac(TM) (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev. 2009, 61:1214-1219.
48. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
49. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 2001, 74:295-302.
50. Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., Shimada Y., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer 2004, 91:1775-1781.
51. Kim T.Y., Kim D.W., Chung J.Y., Shin S.G., Kim S.C., Heo D.S., Kim N.K., Bang Y.J. Phase I and pharmacokinetic study of genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10:3708-3716.
52. Bhatt R., Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., Klein P. Synthesis and in vivo antitumor activity of Poly(l-glutamic acid) conjugates of 20(S)-camptothecin. J. Med. Chem. 2003, 46:190-193.
53. Sabbatini P., Aghajanian C., Dizon D., Anderson S., Dupont J., Brown J.V., Peters W.A., Jacobs A., Mehdi A., Rivkin S., Eisenfeld A.J., Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2004, 22:4523-4531.
54. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
55. Pelicano H., Martin D.S., Xu R.H., Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:4633-4646.
56. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74:7-25.
57. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46:169-185.
58. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 1989, 6:193-210.
59. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the anti-tumor agent smancs. Cancer Res. 1986, 46:6387-6392.
60. Brenner B.M., Hostetter T.H., Humes H.D. Glomerular permselectivity: barrier function based on discrimination of molecular size and charge. Am. J. Physiol. 1978, 234:F455-F460.
61. Maack T., Johnson V., Kau S.T., Figueiredo J., Sigulem D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979, 16:251-270.
62. Mihara K., Hojo T., Fujikawa M., Takakura Y., Sezaki H., Hashida M. Disposition characteristics of protein drugs in the perfused rat kidney. Pharm. Res. 1993, 10:823-827.
63. Mihara K., Mori M., Hojo T., Takakura Y., Sezaki H., Hashida M. Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 1993, 16:158-162.
64. Fujita T., Nishikawa M., Tamaki C., Takakura Y., Hashida M., Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 1992, 263:971-978.
65. Mahato R.I., Kawabata K., Takakura Y., Hashida M. In vivo disposition characteristics of plasmid DNA complexed with cationic liposomes. J. Drug Target. 1995, 3:149-157.
66. Ma S.F., Nishikawa M., Katsumi H., Yamashita F., Hashida M. Cationic charge-dependent hepatic delivery of amidated serum albumin. J. Control Release 2005, 102:583-594.
67. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
68. Ulbrich K., Subr V. Polymeric anticancer drugs with pH controlled activation. Adv. Drug Deliv. Rev. 2004, 23:1023-1050.
69. Torchilin V.P. Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv. 2005, 2:319-327.
70. Zeng F., Liu J., Allen C. Synthesis and characterization of biodegradable poly(ethylene glycol)-block-poly(5-benzyloxy-trimethylene carbonate) copolymers for drug delivery. Biomacromolecules 2004, 5:1810-1817.
71. Roby A., Erdogan S., Torchilin V.P. Solubilization of poorly soluble PDT agent, mesotetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur. J. Pharm. Biopharm. 2006, 62:235-240.
72. Bartels C.L., Wilson A.F. How does a novel formulation of paclitaxel affect drug delivery in metastatic breast cancer?. US Pharm. 2004, 29:HS18.
73. Garber K. Improved paclitaxel formulation hints at new chemotherapy approach. J. Natl Cancer Inst. 2004, 96:90-91.
74. Tsukagoshi S. A new LH-RH agonists for treatment of prostate cancer, 3month controlled release formulation of goserelin acetate (Zoladex LA 10.8mg depot). Outline of preclinical and clinical studies. Gan To Kagaku Ryoho 2002, 29:1675-1687.
75. Heyns C.F., Simonin M.P., Grosgurin P., Schall R., Porchet H.C. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003, 92:226-231.
76. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
77. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54:631-651.
78. Singer J.W., Shaffer S., Baker B., Bernareggi A., Stromatt S., Nienstedt D., Besman M. Paclitaxel polyglumex (XYOTAX; CT-2103) [XYOTAX TM]: an intracellularly targeted taxane. Anti-cancer Drug 2005, 16:243-254.
79. Springett G.M., Takimoto C., McNamara M., Doroshow J.H., Syed S., Eastham E., Spriggs D., Pezzulli S., Michelson G., Dupont J. Phase 1 study of CT2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol. 2004, 22:3127. Suppl. S.
80. Maria V.J., Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 2006, 24:39-47.
81. Rejmanova P., Kopecek J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide) copolymers. Biomaterials 1985, 6:45-48.
82. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 1994, 70:636-641.
83. Seymour L.W., Ulbrich K., Strohalm J., Kopecek J., Duncan R. Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 1990, 39:1125-1131.
84. Ulbrich K., Etrych T., Chytil P., Jelínková M., Ríhová B. Antibody targeted polymer-doxorubicin conjugates with pH controlled activation. J Drug Target. 2004, 12:477-489.
85. Omelyanenko V., Kopecková P., Gentry C., Shiah J.G., Kopecek J. HPMA copolymer-anticancer drug-OV-TL-TL16 antibody conjugates. 1. Influence of the method of the synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in-vitro. J Drug Target. 1996, 3:357-373.
86. Wan K.W., Vicent M., Duncan R. Targeting endothelial cells using HPMA copolymer-doxorubicin-RGD conjugates. Proc. Int'l Symp. Control. Rel. Bioact. Mater. 2003, 30:491-492.
87. Maeda H., Sawa T., Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control Release 2001, 74:47-61.
88. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32:e149.
89. Kircheis R., Blessing T., Brunner S., Wightman L., Wagner E. Tumor targeting with surface shielded ligand-polycation DNA complexes. J. Control. Release 2001, 72:165-170.
90. Kim S.H., Jeong J.H., Cho K.C., Kim S.W., Park T.G. Target-specific gene silencing by siRNA plasmid DNA complexed with folate-modified poly(ethylenimine). J. Control. Release 2005, 104:223-232.
91. Suh W., Han S.O., Yu L., Kim S.W. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol. Ther. 2002, 6:664-672.
92. Kursa M., Walker G.F., Roessler V., Ogris M., Roedl W., Kircheis R., Wagner E. Novel shielded transferrin-polyethylene glycol-polyethylenimine/DNA complexes for systemic tumortargeted gene transfer. Bioconjug. Chem. 2003, 14:222-231.
93. Lee H., Kim T.H., Park T.G. A receptor-mediated gene delivery system using streptavidin and biotin-derivatized, pegylated epidermal growth factor. J. Control. Release 2002, 83:109-119.
94. Merdan T., Callahan J., Petersen H., Kunath K., Bakowsky U., Kopeckova P., Kissel T., Kopecek J. Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene delivery to human ovarian carcinoma cells. Bioconjug. Chem. 2003, 14:989-996.
95. Natarajan A., Xiong C.Y., Albrecht H., DeNardo G.L., DeNardo S.J. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Bioconjug. Chem. 2005, 16:113-121.
96. Torchilin V.P. Drug targeting. Eur. J. Pharm. Sci. 2000, 11:S81-S91.
97. Gref R., Domb A.J., Quellec P., Blunk T., Muller R.H., Verbavatz J.M., Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16:215-233.
98. Delgado C., Francis G.E., Fisher D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9:249-304.
99. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control. Release 2000, 69:1-25.
100. Greenwald R.B., Conover C.D., Choe Y.H. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev. Ther. Drug Carrier Syst. 2000, 17:101-161.
101. Kommareddy S., Shenoy D.B., Amiji M. Nanoparticulate carriers of gelatin and gelatin derivatives. Biological and Pharmaceutical Nanomaterials 2005, 330-347. Wiley-VCH, Weinheim, Germany. C. Kumar (Ed.).
102. Torchilin V.P. How do polymers prolong circulation time of liposomes?. J. Liposome Res. 1996, 6:99-116.
103. Oupicky D., Howard K.A., Konak C., Dash P.R., Ulbrich K., Seymour L.W. Steric stabilization of poly-l-lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]. Bioconjug. Chem. 2000, 11:492-501.
104. Fenske D.B., MacLachlan I., Cullis P.R. Long-circulating vectors for the systemic delivery of genes. Curr. Opin. Mol. Ther. 2001, 3:153-158.
105. Krause H.J., Schwarz A., Rohdewald P. Interfacial polymerization, a useful method for the preparation of polymethylcyanoacrylate nanoparticles. Drug Dev. Ind. Pharm. 1986, 12:527-552.
106. Murthy R.S.R., Harivardhan Reddy L. Poly(alkyl cyanoacrylate) nanoparticles for delivery of anti-cancer drugs. Nanotechnology for cancer therapy 2007, 251-288. Taylor & Francis Group, LLC., FL. M.M. Amiji (Ed.).
107. Seijo B. Design of nanoparticles of less than 50nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 1990, 62:1-7.
108. Reddy L.H., Murthy R.S.R. Influence of polymerization technique and experimental variables on the particle properties and release kinetics of methotrexate from poly(butylcyanoacrylate) nanoparticles. Acta Pharm. 2004, 54:103-118.
109. Couvreur P., Kante B., Roland M., Speiser P. Adsorption of antineoplastic drugs to polyalkyl cyanoacrylate nanoparticles and their release in calf serum. J. Pharm. Sci. 1979, 68:1521-1524.
110. Kreuter J., Hartman H.R. Comparative study on the cytostatic effects and tissue distribution of 5-fluorouracil in a free from and bound to polybutylcyanocrylate nanoparticles in sarcoma 180-bearing mice. Oncology 1983, 40:363.
111. Marchal-Heussler L., Maincent P., Hoffman H., Spittler J., Couvereur P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutyl cyanoacrylate nanoparticle preparations. Int. J. Pharm. 1990, 58:115-122.
112. Brasseur N., Brault D., Couvreur P. Adsorption of hematoporphyrin onto polyalkyl cyanoacrylate nanoparticles: carrier capacity and drug release. Int. J. Pharm. 1991, 70:129-135.
113. Gaspar R., Preat V., Roland M. Nanoparticles of polyisohexyl cyanoacrylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity. Int. J. Pharm. 1991, 68:111-119.
114. Verdun C., Couvreur P., Vranckx H., Lenaerts V., Roland M. Development of a nanoparticle controlled-release formulation for human use. J. Control. Release 1986, 3:205-210.
115. Illum L., Khan M.A., Mak E., Davis S.S. Evaluation of carrier capacity and release characteristic for poly(butyl-2-cyanoacrylate) nanoparticles. Int. J. Pharm. 1986, 30:17-28.
116. Harmia T., Speiser P., Kreuter J. Optimization of pilocarpine loading onto nanoparticles by sorption procedures. Int. J. Pharm. 1986, 33:45-54.
117. Simeonova M., Velichkova R., Ivanova G., Enchev V., Abrahams I. Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. J. Drug Target. 2004, 12:49-56.
118. Stella B., Arpicco S., Peracchia M.T., Desmaële D., Hoebeke J., Renoir M., D'Angelo J., Cattel L., Couvreur P. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 2000, 89:1452-1464.
119. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55:329-347.
120. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-coglycolide) (PLGA) devices. Biomaterials 2000, 21:2475-2490.
121. Hanafusa S., Matsusue Y., Yasunaga T., Yamamuro T., Oka M., Shikinami Y., Ikada Y. Biodegradable plate fixation of rabbit femoral shaft osteotomies. A comparative study. Clin. Orthop. Relat. Res. 1995, 315:262-271.
122. Matsusue Y., Hanafusa S., Yamamuro T., Shikinami Y., Ikada Y. Tissue reaction of bioabsorbable ultra high strength poly(l-lactide) rod. A long-term study in rabbits. Clin. Orthop. Relat. Res. 1995, 317:246-253.
123. Langer R. Tissue engineering: a new field and its challenges. Pharm. Res. 1997, 14:840-841.
124. Mooney D.J., Sano K., Kaufmann P.M., Majahod K., Schloo B., Vacanti J.P., Langer R. Long-term engraftment of hepatocytes transplanted on biodegradable polymer sponges. J. Biomed. Mater. Res. 1997, 37:413-420.
125. Sahoo S.K., Ma W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 2004, 112:335-340.
126. Kim S.H., Jeong J.H., Chun K.W., Park T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(l-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005, 21:8852-8857.
127. Mo Y., Lim L.Y. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J. Control. Release 2005, 108:244-262.
128. Cegnar M., Premzl A., Zavasnik-Bergant V., Kristl J., Kos J. Poly(lactide-co-glycolide) nanoparticles as a carrier system for delivering cysteine protease inhibitor cystatin into tumor cells. Exp. Cell Res. 2004, 301:223-231.
129. Yoo H.S., Lee K.H., Oh J.E., Park T.G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J. Control. Release 2000, 68:419-431.
130. Zhang L., Chan J.M., Gu F.X., Rhee J.-W., Wang A.Z., Radovic-Moreno A.F., Alexis F., Langer R., Farokhzad O.C. Self-assembled lipid polymer hybrid nanoparticles: a robust drug delivery platform. Am. Chem. Soc. 2008, 2:1696-1702.
131. Hu C.-M.J., Kaushal S., Cao H.S.T., Aryal S., Sartor M., Esener S., Bouvet M., Zhang L. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol. Pharm. 2010, 7:914-920.
132. Kwon G., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Biodistribution of micelle-forming polymer-drug conjugates. Pharm. Res. 1993, 10:970-974.
133. Kwon G., Suwa S., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J. Control Release 1994, 29:17-23.
134. Kohori F., Sakai K., Aoyagi T., Yokoyama M., Sakurai Y., Okano T. Preparation and characterization of thermally responsive block copolymer micelles comprising poly(N-isopropylacrylamide-b-DL-lactide). J. Control Release 1998, 55:87-98.
135. Chung J.E., Yokoyama M., Aoyagi T., Sakurai Y., Okano T. Effect of molecular architecture of hydrophobically modified poly(N-isopropylacrylamide) on the formation of thermoresponsive core-shell micellar drug carriers. J. Control Release 1998, 53:119-130.
136. Le Garrec D., Taillefer J., Van Lier J.E., Lenaerts V., Leroux J.C. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J. Drug Target. 2002, 10:429-437.
137. Ashwell G., Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 1982, 51:531-554.
138. Kuiper J. The Liver: Biology and Pathobiology 1994, Raven Press, New York. 3rd.
139. Newkome G.R., Yao Z., Baker G.R., Gupta V.K. Cascade molecules: a new approach to micelles, A[27]-arborol. J. Org. Chem. 1985, 50:2003-2004.
140. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30:53-65.
141. Scholes P.D., Coombes A.G., Illum L., Davis S.S., Watts J.F., Ustariz C., Vert M., Davies M.C. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J. Control. Release 1999, 59:261-278.
142. Chawla J.S., Amiji M.M. Cellular uptake and concentrations of tamoxifen upon administration in poly(epsilon-caprolactone) nanoparticles. AAPS PharmSci 2003, 5:E3.
143. Hu H., Zhao B., Itkis M.E., Haddo R.C. Nitric acid purification of single-walled carbon nanotubes. J. Phys. Chem. B 2003, 107:13838-13842.
144. Liang F., Chen B. A review on biomedical applications on single-walled carbon nanotubes. Curr. Med. Chem. 2010, 17:10-24.
145. Bethune D.S., Klang C.H., de Vries M.S., Gorman G., Savoy R., Vazquez J., Beyers R. Cobalt-catalysed growth of carbon nanotubes with single-atomic-layer walls. Nature 1993, 363:605-607.
146. Thess A., Lee R., Nikolaev P., Diah H., Petit P., Robert J., Xu C., Fischer J.E., Samalley R.E. Crystalline ropes of metallic nanotubes. Science 1996, 273:483-487.
147. Cassel A.M., Raymakers J.A., Kong J., Dia H. Large scale CVD synthesis of single-walled carbon nanotubes. J. Phys. Chem. B 1999, 103:6484-6492.
148. Park T., Banerjee S., Hemraj-Bennya T., Wong S.S. Purification strategies and purity visualization techniques for single-walled carbon nanotubes. J. Mater. Chem. 2006, 16:141-154.
149. Hirlekar R., Yamagar M., Garse H., Vij M., Kadam V. Carbon nanotubes and its applications: a review. Asian J. Pharm.Clin. Res. 2009, 2:17-27.
150. Bianco A., Kostarelos K., Partidos C.D., Prato M. Biomedical applications of functionalised carbon nanotubes. Chem. Commun. 2005, 571-577.
151. Bonifazi D., Nacci C., Marega R., Campidelli S., Ceballos G., Modesti S., Meneghetti M., Prato M. Microscopic and spectroscopic characterization of paint brush-like single-walled carbon nanotubes. Nano Lett. 2006, 6:1408-1414.
152. Zhao B., Hu H., Yu A., Perea D., Haddon R.C. Synthesis and characterization of water soluble single-walled carbon nanotube graft copolymers. J. Am. Chem. Soc. 2005, 127:8197-8203.
153. Malarkey E.B., Reyes R.C., Zhao B., Haddon R.C., Parpura V. Water soluble single-walled carbon nanotubes inhibit stimulated endocytosis in neurons. Nano Lett 2008, 8:3538-3542.
154. Malarkey E.B., Fisher K.A., Bekyarova E., Liu W., Haddon R.C., Parpura V. Conductive single-walled carbon nanotube substrates modulate neuronal growth. Nano Lett 2009, 9:264-268.
155. Lay C.L., Liu H.Q., Tan H.R., Liu Y. Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics. Nanotechnology 2010, 21:065101.
156. Prato M., Kostarelos K., Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 2008, 41:60-68.
157. Tagmatarchis N., Prato M. Functionalization of carbon nanotubes via 1,3-dipolar cycloadditions. J. Mater. Chem. 2004, 14:437-439.
158. Chen J., Meziani M.J., Sun Y.P., Cheng S.H. Poly(ethylene glycol)-conjugated multi-walled carbon nanotubes as an efficient drug carrier for overcoming multi drug resistance. Toxicol. Appl. Pharmacol. 2011, 250:184-193.
159. Kostarelos K., Lacerda L., Pastorin G., Wu W., Wieckowski S., Luangsivilay J., Godefroy S., Pantarotto D., Briand J.P., Muller S., Prato M., Bianco A. Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. Nat. Nanotechnol. 2007, 2:108-113.
160. Liu Z., Tabakman S.M., Chen Z., Dai H. Preparation of carbon nanotube bioconjugates for biomedical applications. Nat. Protoc. 2009, 4:1372-1382.
161. Liu Z., Fan A.C., Rakhra K., Sherlock S., Goodwin A., Chen X., Yang Q., Felsher D.W., Dai H. Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy. Angew. Chem. Int. Ed Engl. 2009, 48:7668-7672.
162. Wu P., Chen X., Hu N., Tam U.C., Blixt O., Zettl A., Bertozzi C.R. Biocompatible carbon nanotubes generated by functionalization with glycodendrimers. Angew. Chem. Int. Ed. 2008, 47:5022-5025.
163. Liu Z., Chen K., Davis C., Sherlock S., Cao Q., Chen X., Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008, 68:6652-6660.
164. Feazell R.P., Nakayama-Ratchford N., Dai H., Lippard S.J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc. 2007, 129:8438-8439.
165. Wu W., Li R., Bian X., Zhu Z., Ding D., Li X., Jia Z., Jiang X., Hu Y. Covalently combining carbon nanotubes with anticancer agent: preparation and antitumor activity. ACS Nano 2009, 3:2740-2750.
166. Kulamarva A., Raja P., Bhathena J., Chen H., Talapatra S., Ajayan P., Nalamasu O., Prakash S. Microcapsulecarbon nanotube devices for therapeutic applications. Nanotechnology 2009, 20:025612.
167. Kulamarva A., Bhathena J., Malhotra M., Sebak S., Nalamasu O., Ajayan P., Prakash S. In vitro cytotoxicity of functionalized single walled carbon nanotubes for targeted gene delivery applications. Nanotoxicology 2008, 2:184-188.
168. Bhirde S.A., Pate V., Gavard J., Zhang G., Sousa A.A., Masedunskas A., Leapman R.D., Weigert R., Gutkind G.S., Rusling J.F. Targeted killing of cancer cells in vivo and in vitro with EGF directed carbon nanotube based drug delivery. ACS Nano 2009, 3:307-316.
169. Krajcik R., Jung A., Hirsch A., Neuhuber W., Zolk O. Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knockdown of genes. Biochem. Biophys. Res. Commun. 2008, 369:595-602.
170. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., Roden R.B.S., Chen Y., Yang R. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 2006, 12:4933-4936.
171. O'Connell M.J., Bachilo S.H., Huffman C.B., Moore V.C., Strano M.S., Haroz E.H., Rialon K.L., Boul P.J., Noon W.H., Kittrell C., Ma J., Hauge R.H., Weisman R.B., Smalley R.E. Band gap fluorescence from individual single-walled carbon nanotubes. Science 2002, 297:593-596.
172. Kam N.W., O'Connell M., Wisdom J.A., Dai H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl Acad. Sci. USA 2005, 102:11600-11605.
173. Shao N., Lu S., Wickstrom E., Panchapakesan B. Integrated molecular targeting of IGF1R and HER2 surface receptors and destruction of breast cancer cells using single wall carbon nanotubes. Nanotechnology 2007, 18:315101.
174. Sayes C.M., Liang F., Hudson J.L., Mendez J., Guo W., Beach J.M., Moore V.C., Doyle C.D., West J.L., Billups W.E., Ausman K.D., Colvin V.L. Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in-vitro. Toxicol. Lett. 2006, 16:135-142.
175. Lacerda L., Bianco A., Prato M., Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. Adv. Drug Deliv. Rev. 2006, 58:1460-1470.
176. Schipper M.L., Nakayama-Ratchford N., Davis C.R., Kam N.W.S., Chu P., Liu Z., Sun X., Dai H., Gambhir S.S. A pilot toxicology study of single-walled carbon nanotubes in a small sample of mice. Nat. Nanotechnol. 2008, 3:216-221.
177. Liu Zhuang, Davis C., Cai W., Hi L., Chen X., Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl Acad. Sci. 2008, 105:1410-1415.
178. Yang S.T., Wang X., Jia G., Gu Y., Wang T., Nie H., Ge C., Wang H., Liu Y. Long-term accumulation and low toxicity of single-walled carbon nanotubes in intravenously exposed mice. Toxicol. Lett. 2008, 181:182-189.
179. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2:47-52.